Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:09 2025-01-24 pm EST			5-day change	1st Jan Change
95.55 ^USD	-1.12%		-2.42%	-3.95%

Jan. 24	Leerink Partners Adjusts Merck Price Target to $118 From $119, Maintains Outperform Rating	MT
Jan. 24	Merck: mixed results in esophageal adenocarcinoma	CF

AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients

December 11, 2024 at 11:15 am EST

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Merck & Co., Inc.

Leerink Partners Adjusts Merck Price Target to $118 From $119, Maintains Outperform Rating	Jan. 24	MT
Merck: mixed results in esophageal adenocarcinoma	Jan. 24	CF
Merck, Eisai Gastroesophageal Cancer Combo Therapy Meets One Primary Endpoint in Trial	Jan. 24	MT
Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study	Jan. 24	DJ
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma	Jan. 24	CI
Edgewise Therapeutics Names Behrad Derakhshan as COO; Shares Fall	Jan. 22	MT
Morgan Stanley Adjusts Merck Price Target to $113 From $123, Maintains Equal Weight Rating	Jan. 21	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Guggenheim Adjusts Price Target on Merck to $122 From $130, Maintains Buy Rating	Jan. 17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Merck & Co., Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 04:30 PM	Jan. 13
GSK Acquiring US-Based IDRx for up to $1.15 Billion	Jan. 13	MT
Philips CEO sees subdued China sales this year	Jan. 13	RE
Leerink Partners Adjusts Price Target on Merck $119 From $136, Keeps Outperform Rating	Jan. 13	MT
Atropos Health, Inc. Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments	Jan. 10	CI
IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma	Jan. 09	MT
Global markets live: Cintas, Amazon, Tesla, Shell, Lufthansa...	Jan. 08
Wall Street's rate cut dreams wane	Jan. 08
UBS Cuts Price Target on Merck to $120 From $125, Maintains Buy Rating	Jan. 08	MT
Merck: HPV vaccine for men approved in China	Jan. 08	CF
Merck Says Gardasil HPV Vaccine Approved for Males in China	Jan. 08	MT
Merck?s GARDASIL® Receives Expanded Approval for Males in China	Jan. 08	CI
Analyst recommendations: Adobe, Merck, Take-Two, Palantir, Experian...	Jan. 08
Truist Securities Downgrades Merck to Hold From Buy, Adjusts Price Target to $110 From $130	Jan. 08	MT

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).

Employees

71,000

Sector

Pharmaceuticals

Calendar

2025-02-04 - Q4 2024 Earnings Release

More about the company